Skip to main navigation
Skip to search
Skip to main content
University of Luebeck Home
English
Deutsch
Home
Research Units
Experts
Publications
Projects
Prizes
Spin-Offs
Media
Activities
Datasets
Search by expertise, name or affiliation
Neue Therapiemöglichkeiten des metastasierten Melanoms
Translated title of the contribution
:
New therapy options of metastasized melanoma
P. Terheyden
*
*
Corresponding author for this work
Clinic of Dermatology, Allergology and Venerology
2
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'New therapy options of metastasized melanoma'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Melanoma
100%
Vemurafenib
33%
Neoplasm
16%
Overall Survival
16%
MEK Inhibitor
16%
T Cell Activation
16%
Tumor Resistance
16%
Tumor Progression
16%
CTLA-4
16%
B Raf Kinase
16%
Pharmacology, Toxicology and Pharmaceutical Science
Melanoma
100%
Vemurafenib
33%
Tumor Growth
16%
Mitogen Activated Protein Kinase Kinase Inhibitor
16%
Tumor Regression
16%
Overall Survival
16%
Neoplasm
16%
Cytotoxic T Lymphocyte Antigen 4
16%
B Raf Kinase
16%